Full-Time

Medical Director

Transplant and Immunology

Posted on 6/24/2025

Celgard

Celgard

201-500 employees

High-performance membranes for energy storage

No salary listed

Morrisville, NC, USA

Hybrid

Hybrid position requiring some in-office presence.

Category
Medical, Clinical & Veterinary (1)
Requirements
  • Doctoral degree in a health sciences-related field (e.g., Pharm.D., M.D., D.O., or Ph.D.)
  • Minimum of 8 years’ experience in the pharmaceutical or biotechnology industry, or a combination of 5+ years of strong clinical/academic experience with demonstrated industry collaboration
  • Solid Organ Transplant therapeutic area experience is required.
  • Demonstrated ability to lead strategic initiatives and work cross-functionally in a matrixed environment.
  • Demonstrated ability, or potential, to excel in smaller entrepreneurial organizations.
  • Strong statistical knowledge with a demonstrated ability to interpret study findings and communicate appropriately.
  • Able to prioritize and work in a fast-paced and changing environment.
  • Exceptional interpersonal, presentation, and communication skills.
  • Innovative thinker, strategic leader, valued collaborator and hands-on tactical performer with a successful track record and a strong drive to succeed.
  • A strong sense of ethics, compliance, and integrity.
  • Ability to travel up to 30% including international and weekend travel.
Responsibilities
  • Leads the development of the annual medical strategic plan together with Medical Affair leadership team and in alignment with Research and Development and Corporate objectives.
  • Contributes to the medical evidence generation strategy, including real-world evidence (RWE), investigator-sponsored studies (IIS), and collaborative research efforts. Provide medical input into clinical development plans, target product profiles, and lifecycle management strategies across pipeline and marketed products.
  • Builds and maintains trusted partnerships with key opinion leaders, academic experts, healthcare providers, patient advocacy groups, and payer decision-makers to inform strategy, guide insight generation, and elevate Veloxis’ leadership in transplant and immunology.
  • Serves as an internal medical advisor to cross functional colleagues and as a transplant medical point of contact for key cross-functional teams and committees.
  • Serves as a core medical contributor to business development, corporate venture capital, and open innovation efforts, including scientific due diligence, asset evaluation, and integration of medical insights into opportunity assessments.
  • Contributes to publication strategy development in partnership with cross-functional colleagues. Ensures timely execution of data dissemination plans that meet scientific, regulatory, and organizational needs.
  • Collaborates with Medical Communications to ensure consistent and high-quality scientific communications across congresses, symposia, digital channels, and educational initiatives.
  • Contributes to content review committee medical accuracy and scientific review of promotional and non-promotional materials.
  • Supports pipeline planning and early-phase development efforts, providing medical input on target product profiles, data interpretation, and clinical differentiation.
  • Leads the conduct of advisory boards and contributes to diverse insight gathering activities.
  • Contributes to the medical grant program, including establishing key objectives and participating in review.
  • Partners with HEOR and Market Access to support value-based evidence generation and to provide direct medical payer engagement, as appropriate.
  • Collaborates closely with the Field Medical teams to ensure strategic alignment, integration of insights into strategic planning, and to support continuous training and relevant content development.
  • Participates in national and regional conferences, meetings, consortia, and other scientific forums, as appropriate, to support medical affairs strategic objectives.
  • Provides coaching and leadership to junior team members and direct reports, fostering a culture of excellence, collaboration, and continuous development.
  • Contributes to the development of SOPs, best practices, and functional standards to ensure medical activities are executed efficiently, ethically, and compliantly. Supports audit readiness and quality improvement initiatives.
  • Actively monitors the changing healthcare landscape to identify emerging global scientific, clinical and health policy trends.

Celgard makes and sells high-performance membrane materials and thin separators used inside batteries, as well as fabrics for outdoor apparel and medical PPE. The membranes sit between battery electrodes to prevent contact while allowing ions to pass, enabling safe and efficient operation in lithium-ion and other chemistries. The company stands out through its Asahi Kasei Group affiliation and strategic alliances (such as with Æsir Technologies) to pursue new battery chemistries, while expanding manufacturing capacity. Its goal is to provide reliable membranes and protective fabrics at scale to support safer, longer-lasting energy storage and protective textiles, and to drive industry growth through collaborations.

Company Size

201-500

Company Stage

N/A

Total Funding

N/A

Headquarters

Charlotte, North Carolina

Founded

N/A

Simplify Jobs

Simplify's Take

What believers are saying

  • Charlotte plant expansion adds 100 jobs, boosts LIB separator capacity for EVs.
  • Asahi Kasei invests in Hipore wet-process coating lines at Charlotte site.
  • Proven separators serve CATL, Panasonic in high-performance EV, ESS applications.

What critics are saying

  • CATL's in-house separators capture 39% EV market, cut Celgard revenue 10-15% by 2027.
  • SK Innovation, Toray wet-process tech displaces dry-process, erodes share in 12 months.
  • Solid-state batteries from Toyota, QuantumScape eliminate separators by 2028.

What makes Celgard unique

  • Celgard specializes in solvent-free dry-process microporous membranes for lithium-ion batteries.
  • Global facilities in USA, China anchor manufacturing for EV battery separators.
  • Strategic alliances with Æsir, Lithion, C4V target Ni-Zn, LFP, BM-LMP batteries.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Company News

Yahoo Finance
Jan 29th, 2024
Celgard and Æsir Technologies Forge Strategic Alliance to Drive Industry Innovation in Nickel-Zinc, Zinc-Air and Lithium-Zinc Batteries

Together, Celgard and Æsir will collaborate on joint research projects to further develop high-technology next-generation Nickel-Zinc (Ni-Zn), Zinc-Air (Zn-Air), Lithium-Zinc (Li-Zn) and Sodium-Zinc (Na-Zn) batteries used primarily in aviation, data centers, telecom, energy infrastructure and electric vehicle (EV) charging applications.

Plant Services
Nov 30th, 2023
Celgard expands North Carolina manufacturing plant to support electric vehicle supply chain

Celgard, LLC has announced plans to expand its manufacturing facility in Charlotte, North Carolina, generating 100 new jobs in the process.

PR Newswire
Oct 31st, 2023
Celgard Charlotte Manufacturing Facility To Expand Battery Separator Capacity And Create New Jobs

Celgard to expand facilities, workforce and product portfolio to better serve the EV battery separator supply chain. Post thisThe Biden-Harris Administration and the U.S. Department of Energy (DOE) have identified the domestic U.S. battery market as a critical supply chain focus area for the nation. Investments in Celgard's Charlotte plant will allow the company to expand existing infrastructure to quickly meet demand of the lithium-ion battery (LIB) separator supply chain and domestic customers.Celgard manufactures dry-process membrane separator also used in vehicle electrification. The company already has a skilled employee base capable of applying technical coatings to base film shipped from Hipore™ sister locations and completing finishing steps required to meet customer specifications

Tamarindo
Jun 13th, 2023
Celgard & Lithion Battery form battery storage alliance | Tamarindo

US-headquartered Celgard, a subsidiary of Polypore International, has formed a strategic alliance with Lithion Battery, whereby the two companies will undertake joint development of battery separators for lithium-ion cells for energy storage systems and microgrids.

PR Newswire Asia
Jun 7th, 2023
Celgard Takes Another Step In Energy Storage Growth As It Forms Strategic Alliance With Lithion Battery For Next-Generation Battery Cells

CHARLOTTE, N.C., June 7, 2023 /PRNewswire/ -- Celgard, LLC (Celgard), a subsidiary of Polypore International, LP (Polypore), is pleased to announce a newly formed strategic alliance with Lithion Battery, Inc. (Lithion), whereby the two companies will undertake joint development of battery separators for next generation lithium-ion cells with Lithium Iron Phosphate (LFP) cathode material. Through this collaborative effort, the companies will meet the ever-growing demand of supplying consistent power to those in need with energy storage systems (ESS) for uses such as micro-grid power applications. The cells could also be deployed in medical tools and military and industrial markets, where Celgard has been providing separator solutions for decades.

INACTIVE